Compare NVTS & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | PACB |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 715.5M |
| IPO Year | N/A | 2010 |
| Metric | NVTS | PACB |
|---|---|---|
| Price | $7.63 | $1.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $5.92 | $2.08 |
| AVG Volume (30 Days) | ★ 15.2M | 7.2M |
| Earning Date | 11-03-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $56,598,000.00 | ★ $154,584,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $11.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $0.85 |
| 52 Week High | $17.79 | $2.73 |
| Indicator | NVTS | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 42.96 |
| Support Level | $7.36 | $1.77 |
| Resistance Level | $8.13 | $2.47 |
| Average True Range (ATR) | 0.58 | 0.14 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 9.38 | 14.10 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.